{"filings":[{"id":79001,"accession_number":"0001493152-26-022898","cik":2025942,"company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","form_type":"8-K","filed_at":"2026-05-14T13:15:35+00:00","items":["7.01","9.01"],"status":"ready","headline":"Curanex completes key Phyto-N milestones; plans Q4 2026 IND for ulcerative colitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed GMP pilot-scale batch of Phyto-N in February 2026 to support IND-enabling studies.","28-day dose-range finding toxicology study in rats and dogs showed no adverse findings at any dose.","Expanded pipeline to include cancer cachexia; global market estimated at $2.54B in 2024.","Cash and equivalents of ~$4.0M as of March 31, 2026, sufficient for near-term development activities.","Targeting Q4 2026 IND submission for ulcerative colitis; Phase I trial to follow FDA review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9665310.169825073,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97288,"accession_number":"0001493152-26-021658","cik":2025942,"company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq grants CURX additional 180 days until Nov 2, 2026 to meet $1 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Nov 5, 2025 for bid price below $1.00; initial 180-day period ended May 4, 2026.","Nasdaq granted second 180-day compliance period through Nov 2, 2026, based on meeting other listing requirements.","Company may implement a reverse stock split to cure the deficiency.","If bid price stays at $1.00 for 10 consecutive days during extension, compliance will be confirmed.","Failure to regain compliance by Nov 2, 2026 could result in delisting, with appeal rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9665310.169825073,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97287,"accession_number":"0001493152-26-014815","cik":2025942,"company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Curanex expands drug pipeline to include cancer cachexia, a multi-billion-dollar market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company adds cancer cachexia as a new core indication beyond its six existing programs (ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, gout).","Global cancer cachexia market was $2.54B in 2024, projected to reach $3.90B by 2033; no approved therapies in US.","Lead program Phyto-N remains in preclinical for ulcerative colitis; Company evaluating further development opportunities in cachexia.","Management sees this as key step in evolving into a broader therapeutics company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9665310.169825073,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111934,"accession_number":"0001493152-26-009155","cik":2025942,"company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Curanex Pharmaceuticals formalizes CEO/COO agreements; base salaries $393,600 and $180,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Jun Liu: annual base salary $393,600, three-year term, plus $3,998/month auto lease.","COO Dr. Liqin Xie: annual salary $180,000, at-will employment, three-month severance on without-cause termination.","CEO served without compensation from Feb 2024 to Aug 2025; received $325,000.08 for past services through March 1, 2026.","Both agreements include 18-month non-compete (CEO), non-solicitation, and clawback provisions under policy effective Aug 12, 2025.","Termination without cause or for good reason triggers 3 months' salary continuation and immediate equity vesting for both."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9665310.169825073,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111933,"accession_number":"0001493152-26-000358","cik":2025942,"company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Curanex CFO Haiyan Yang resigns; Wanjun Zhang appointed effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Haiyan Yang resigned as CFO and Treasurer effective Dec 31, 2025; no disagreement cited.","Wanjun Zhang appointed as CFO and Treasurer effective Jan 1, 2026.","Zhang has 20+ years experience; previously finance director at Perfect World (PWRD).","Compensation: $20,000 per year under consulting agreement; independent contractor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9665310.169825073,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128554,"accession_number":"0001493152-25-021028","cik":2025942,"company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Curanex Pharmaceuticals receives Nasdaq bid price deficiency notice; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Nov 5, 2025 for bid price below $1.00 for 30 consecutive days.","Has until May 4, 2026 (180 days) to regain compliance with Minimum Bid Price.","If not cured, may qualify for additional 180-day period if eligible and cures with reverse split if needed.","Stock continues trading under symbol CURX on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9665310.169825073,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145346,"accession_number":"0001493152-25-015986","cik":2025942,"company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Curanex repays $408.5K in related-party loans, issues 28,312 shares for $200K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 28,312 shares to Xiaohong Song for $200,000 under amended subscription agreement; shares are 0.1% of total outstanding.","Prepaid $408,537.32 on two promissory notes owed to CEO's wife (Dian Ying Jing), eliminating all outstanding company debt.","Notes carried 4.34% interest with 2027 maturities; prepayment saved ~$26,183 in future interest payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9665310.169825073,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145345,"accession_number":"0001493152-25-013167","cik":2025942,"company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Curanex Pharma underwriters exercise full over-allotment; additional $2.25M raised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over-allotment option exercised in full; 562,500 shares at $4.00, raising additional $2.25M.","Total IPO gross proceeds: $17.25M from 4,312,500 shares.","Shares outstanding after overallotment: 28,312,500.","Lead underwriter Dominari Securities; co-underwriters Pacific Century and Revere.","Company advances botanical drug Phyto-N for inflammatory diseases, targeting Phase I."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9665310.169825073,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145344,"accession_number":"0001493152-25-012404","cik":2025942,"company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Curanex Pharmaceuticals closes IPO of 3.75M shares at $4.00, raising $15M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $15M from IPO of 3,750,000 shares at $4.00 per share on firm commitment basis.","Net proceeds approximately $12.1M after underwriting discounts and estimated offering expenses.","Common stock began trading on Nasdaq Capital Market on Aug 26, 2025 under ticker CURX.","Underwriters granted 45-day option to purchase up to 562,500 additional shares at $4.00 per share.","Lead underwriter Dominari Securities LLC; co-underwriters Pacific Century Securities LLC and Revere Securities LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9665310.169825073,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145343,"accession_number":"0001493152-25-012316","cik":2025942,"company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Curanex Pharmaceuticals prices IPO of 3.75M shares at $4.00/share, gross $15M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $15M from 3.75M shares at $4.00/share; net proceeds ~$12.1M after underwriting discounts and expenses.","Shares expected to begin trading on Nasdaq (CURX) on Aug 26, 2025; close expected Aug 27, 2025.","Underwriters have 45-day option to purchase up to 562,500 additional shares to cover over-allotments.","Proceeds to fund Phyto-N (ulcerative colitis) development, GLP toxicology/pharmacokinetic studies, IND submission, and working capital.","Lead underwriter: Dominari Securities; co-underwriters: Pacific Century Securities and Revere Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9665310.169825073,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}